Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

liraglitude

- PMLiVE

FDA to review restrictions on GSK’s diabetes drug Avandia

Advisory committee to discuss re-analysis of diabetes drug’s safety data

- PMLiVE

FDA gives priority review status to BMS/ AZ’s metreleptin

Former obesity prospect has potential in the rare disease lipodystrophy

- PMLiVE

ASCO: Merck and BMS trumpet melanoma trials

Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab

Sanofi reception

Sanofi gives up on iniparib and otamixaban

Drops cancer drug and anticoagulant after negative late-stage trials

- PMLiVE

Novo files for EU approval of Tresiba/ Victoza combination in diabetes

Ideglira combines insulin degludec and GLP-1 analogue

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

Boehringer/ Lilly launch online diabetes management game

Pharma companies aim to raise awareness of type 2 diabetes complications

- PMLiVE

Novo Nordisk on track to file liraglutide in obesity

Expects regulatory filings in the US and EU by the beginning of 2014

- PMLiVE

US FDA approves Roche’s assay as first blood test to diagnose diabetes

Will help catch diabetes early in country where seven million people are undiagnosed

Wireless pill bottle wins Boehringer healthcare innovation prize

AdhereTech's winning entry aims to increase patient adherence

- PMLiVE

A look back at Sanofi’s merger with Synthélabo

This month, in 1999: How two pharma companies came together to create a giant

Sanofi reception

Sanofi reconsiders closure plans in Toulouse after government pressure

Report says research site can remain open with minimal job losses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links